Guo Yixin, Wu Peiyi, Liao Qiwei, Huang Zhuo
Foshan Clinical Medical School of Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Medicine (Baltimore). 2024 Dec 13;103(50):e40042. doi: 10.1097/MD.0000000000040042.
This study estimates the research upon the potential worth of Ras association domain family member 1 A (RASSF1A) and short stature homeobox 2 (SHOX2) DNA methylation in lung cancer (LC) diagnosis.
Open-published research was searched through PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, and Chinese Biology Medicine Literature Database. Data on true positives, false positives, false negatives, and true negatives were extracted.
This meta-analysis included 22 studies encompassing 4109 subjects (2427 LC patients and 1682 controls). The combined sensitivity, specificity, and area under the curve for RASSF1A and SHOX2 DNA methylation were 0.77 (95% CI: 0.71-0.81), 0.90 (95% CI: 0.87-0.92), and 0.92 (95% CI: 0.87-0.92), respectively. The pooled positive likelihood ratio and negative likelihood ratio were 7.5 (5.9-9.7) and 0.26 (0.21-0.32). The combined diagnostic odds ratio was 29 (95% CI: 20-41).
RASSF1A and SHOX2 DNA methylation may emerge as potential diagnostic biomarkers for early-stage LC.
本研究评估了Ras关联结构域家族成员1A（RASSF1A）和矮小同源框2（SHOX2）DNA甲基化在肺癌（LC）诊断中的潜在价值。
通过PubMed、EMBASE、Cochrane图书馆、Web of Science、中国知网和中国生物医学文献数据库检索公开发表的研究。提取真阳性、假阳性、假阴性和真阴性数据。
该荟萃分析纳入了22项研究，共4109名受试者（2427例LC患者和1682例对照）。RASSF1A和SHOX2 DNA甲基化的合并敏感性、特异性和曲线下面积分别为0.77（95%CI：0.71-0.81）、0.90（95%CI：0.87-0.92）和0.92（95%CI：0.87-0.92）。合并阳性似然比和阴性似然比分别为7.5（5.9-9.7）和0.26（0.21-0.32）。合并诊断比值比为29（95%CI：20-41）。
RASSF1A和SHOX2 DNA甲基化可能成为早期LC的潜在诊断生物标志物。
